乌鸦传媒

The quiet retraction of a has shone a light on publishers' desire "to put out huge volumes of studies while avoiding the reputational damage of retracting them publicly." (New York Times)

The FDA is behind schedule on providing guidance to drug and device makers about how to increase . (Regulatory Focus)

A bipartisan group of senators sent FDA Commissioner Robert Califf, MD, a letter encouraging action to curb promoting benefits of drugs on social media. (Wall Street Journal)

Pretreatment with a histone deacetylase inhibitor led to encouraging response rates with immunotherapy for , particularly triple-negative breast cancer (TNBC). (Johns Hopkins Medicine, Nature Cancer)

Assessment of with multigene panels increased healthcare costs with no significant improvement in overall survival. (ESMO, eClinicalMedicine)

A Belgian boy has become the first child known to be known as brainstem glioma. (Science Alert)

A federal judge dismissed a lawsuit by Pharmaceutical Research and Manufacturers of America challenging the Biden administration's plan to allow Medicare to . (Reuters)

Neoadjuvant immunotherapy for led to an encouraging 2-year survival of 82-90%. (University of Texas MD Anderson Cancer Center, Nature Cancer)

Physical activity was associated with significantly less . (Cancer)

G1 Therapeutics announced termination of a phase III trial of trilaciclib (Cosela) in because of lack of efficacy but will continue a phase III trial of the drug in . (Reuters)

Comment